Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis

Journal of Nuclear Medicine

Volumn 42, Issue 1, 2001, Pages 9-16

  Avril, N ^a   Menzel, M ^a   Dose, J ^a   Schelling, M ^a   Weber, W ^a   Janicke F ^a   Nathrath, W ^a   Schwaiger, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; FDG; Histology; Immunohistochemistry; Metabolism; PET

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER; PROGESTERONE RECEPTOR;

ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CELL ENERGY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALIGNANT TRANSFORMATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035132776     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
2. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
3. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
4. Breast imaging with fluorine-18-FDG PET: Quantitative image analysis
5. Qualitative F-18 FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
6. Association between F-18 fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation
7. Utility of PET in breast cancer
8. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations
9. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake
10. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography
11. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma. I. Are inflammatory cells important?
12. Overexpression of Glut-1 glucose transporter in human breast cancer: An immunohistochemical study
13. Histological grading and prognosis in breast cancer
14. Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin-fixed paraffin sections of breast carcinoma
15. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue
16. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors
17. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: An unsolved problem
18. Invasive lobular carcinoma of the breast: Mammographic findings and extent of disease at diagnosis in 184 patients
19. Nonpalpable breast tumors: Diagnosis with contrast-enhanced subtraction dynamic MR imaging
20. Invasive lobular carcinoma: Sonographic appearance and role of sonography in improving diagnostic sensitivity
21. Characterisation of macrophages infiltrating human mammary carcinomas
22. Detection and quantitation of macrophage infiltration into primary human tumors with the use of cell-surface markers
23. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells
24. 2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation
25. 18F]-D-glucose
26. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry
27. Glucose utilization of cerebral gliomas measured by [F-18] fluorodeoxyglucose and positron emission tomography
28. Prediction of survival in glioma patients by means of positron emission tomography
29. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography
30. Noninvasive grading of musculoskeletal tumors using PET
31. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: Is a non-invasive determination of biological activity possible?
32. Proliferation markers in breast carcinoma: Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1
33. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity
34. Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays
35. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study
36. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma
37. Regulation of glucose-transporter gene expression in vitro and in vivo
38. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes
39. Glucose catabolism in cancer cells: Amplification of the gene encoding type II hexokinase
40. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis